- Home
- KALA vs CRIS Comparison
KALA vs CRIS Comparison
Compare KALA & CRIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KALA
- CRIS
- Stock Information
- Founded
- KALA 2009
- CRIS 2000
- Country
- KALA United States
- CRIS United States
- Employees
- KALA N/A
- CRIS N/A
- Industry
- KALA Biotechnology: Pharmaceutical Preparations
- CRIS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KALA Health Care
- CRIS Health Care
- Exchange
- KALA Nasdaq
- CRIS Nasdaq
- Market Cap
- KALA 26.2M
- CRIS 22.9M
- IPO Year
- KALA 2017
- CRIS 2000
- Fundamental
- Price
- KALA $8.58
- CRIS $1.73
- Analyst Decision
- KALA Strong Buy
- CRIS Strong Buy
- Analyst Count
- KALA 3
- CRIS 2
- Target Price
- KALA $14.00
- CRIS $16.50
- AVG Volume (30 Days)
- KALA 183.0K
- CRIS 62.8K
- Earning Date
- KALA 08-08-2025
- CRIS 08-05-2025
- Dividend Yield
- KALA N/A
- CRIS N/A
- EPS Growth
- KALA N/A
- CRIS N/A
- EPS
- KALA N/A
- CRIS N/A
- Revenue
- KALA N/A
- CRIS $11,405,000.00
- Revenue This Year
- KALA N/A
- CRIS N/A
- Revenue Next Year
- KALA N/A
- CRIS $9.52
- P/E Ratio
- KALA N/A
- CRIS N/A
- Revenue Growth
- KALA N/A
- CRIS 12.24
- 52 Week Low
- KALA $2.92
- CRIS $1.02
- 52 Week High
- KALA $11.20
- CRIS $8.29
- Technical
- Relative Strength Index (RSI)
- KALA 67.01
- CRIS 47.07
- Support Level
- KALA $7.38
- CRIS $1.65
- Resistance Level
- KALA $7.71
- CRIS $1.88
- Average True Range (ATR)
- KALA 0.79
- CRIS 0.13
- MACD
- KALA 0.03
- CRIS 0.02
- Stochastic Oscillator
- KALA 92.58
- CRIS 54.55
About KALA KALA BIO Inc.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.